RhumbLine Advisers
TRVI icon

RhumbLine Advisers’s Trevi Therapeutics TRVI Stock Holding History

RhumbLine Advisers’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Buy
132,463
+23,402
+21% +$340K ﹤0.01% 1839
2026
Q1 		$1.3M Buy
109,061
+3,139
+3% +$35.1K ﹤0.01% 2065
2025
Q4 		$1.33M Sell
105,922
-9,100
-8% -$105K ﹤0.01% 2078
2025
Q3 		$1.05M Buy
115,022
+8,620
+8% +$64.6K ﹤0.01% 2217
2025
Q2 		$582K Buy
106,402
+15,920
+18% +$99K ﹤0.01% 2592
2025
Q1 		$569K Buy
90,482
+10,608
+13% +$50.6K ﹤0.01% 2491
2024
Q4 		$329K Sell
79,874
-2,097
-3% -$6.71K ﹤0.01% 2938
2024
Q3 		$274K Buy
81,971
+6,753
+9% +$20.1K ﹤0.01% 3071
2024
Q2 		$224K Buy
75,218
+23,263
+45% +$64.6K ﹤0.01% 3164
2024
Q1 		$179K Buy
51,955
+491
+1% +$1.1K ﹤0.01% 3231
2023
Q4 		$69K Sell
51,464
-2,808
-5% -$4.25K ﹤0.01% 3557
2023
Q3 		$118K Buy
54,272
+4,215
+8% +$9.52K ﹤0.01% 3404
2023
Q2 		$120K Buy
+50,057
New +$126K ﹤0.01% 3450

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

RhumbLine Advisers's TRVI Position: Q2 2026 in Review

RhumbLine Advisers increased its Trevi Therapeutics (TRVI) stake by 21% in Q2 2026, buying an estimated $340K and bringing the position to 132,463 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1839.

RhumbLine Advisers first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • RhumbLine Advisers held 132,463 shares of Trevi Therapeutics worth $2.47M as of Q2 2026.
  • RhumbLine Advisers bought 23,402 Trevi Therapeutics shares in Q2 2026, an estimated $340K.
  • Trevi Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1839 holding.
  • RhumbLine Advisers first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.